ACS Medicinal Chemistry Letters
Letter
genes producing TRK oncogenes in papillary thyroid carcinomas.
Genomics 1995, 28, 15−24.
(13) Greco, A.; Mariani, C.; Miranda, C.; Pagliardini, S.; Pierotti, M.
A. Characterization of the NTRK1 genomic region involved in
chromosomal rearrangements generating TRK oncogenes. Genomics
1993, 18, 397−400.
(14) Bounacer, A.; Schlumberger, M.; Wicker, R.; Du-Villard, J. A.;
Caillou, B.; Sarasin, A.; Suarez, H. G. Search for NTRK1 proto-
oncogene rearrangements in human thyroid tumours originated after
therapeutic radiation. Br. J. Cancer 2000, 82, 308−314.
(15) Beimfohr, C.; Klugbauer, S.; Demidchik, E. P.; Lengfelder, E.;
Rabes, H. M. NTRK1 re-arrangement in papillary thyroid carcinomas
of children after the Chernobyl reactor accident. Int. J. Cancer 1999,
80, 842−847.
(16) Tognon, C.; Knezevich, S. R.; Huntsman, D.; Roskelley, C. D.;
Melnyk, N.; Mathers, J. A.; Becker, L.; Carneiro, F.; MacPherson, N.;
Horsman, D.; Poremba, C.; Sorensen, P. H. B. Expression of the
ETV6-NTRK3 gene fusion as a primary event in human secretory
breast carcinoma. Cancer Cell 2002, 2, 367−376.
(17) Lannon, C. L.; Sorensen, P. H. B. ETV6-NTRK3: A chimeric
protein tyrosine kinase with transformation activity in multiple cell
lineages. Semin. Cancer Biol. 2005, 15, 215−223.
(18) Watanabe, N.; Kobayashi, H.; Hirama, T.; Kikuta, A.; Koizumi,
S.; Tsuru, T.; Kaneko, Y. Cryptic t(12;15)(p13;q26) producing the
ETV6-NTRK3 fusion gene and no loss of IGF2 imprinting in
congenital mesoblastic nephroma with trisomy 11 fluorescence in situ
hybridization and IGF2 allelic expression analysis. Cancer Genet.
Cytogenet. 2002, 136, 10−16.
(19) Izbicka, E.; Izbicki, T. Therapeutic strategies for the treatment of
neuroblastoma. Curr. Opin. Invest. Drugs 2005, 6, 1200−1214.
(20) Douma, S.; Van Laar, T.; Zevenhoven, J.; Meuwissen, R.; Van
Garderen, E.; Peeper, D. S. Suppression of anoikis and induction of
metastasis by the neurotrophic receptor TRKB. Nature 2004, 430,
1034−1039.
(21) Miknyoczki, S. J.; Chang, H.; Klein-Szanto, A.; Dionne, C. A.;
Ruggeri, B. A. The TRK tyrosine kinase inhibitor CEP-701 (KT-5555)
exhibits significant antitumor efficacy in preclinical xenograft models of
human pancreatic ductal adenocarcinoma. Clin. Cancer Res. 1999, 5,
2205−2212.
(22) Ketterer, K.; Rao, S.; Friess, H.; Weiss, J.; Buechler, M. W.;
Korc, M. Reverse transcription-PCR analysis of laser-captured cells
points to potential paracrine and autocrine actions of neurotrophins in
pancreatic cancer. Clin. Cancer Res. 2003, 9, 5127−5136.
(23) Sclabas, G. M.; Fujioka, S.; Schmidt, C.; Li, Z.; Frederick, W. A.
I.; Yang, W.; Yokoi, K.; Evans, D. B.; Abbruzzese, J. L.; Hess, K. R.;
Zhang, W.; Fidler, I. J.; Chiao, P. Overexpression of tropomysin-
related kinase B in metastatic human pancreatic cancer cells. Clin.
Cancer Res. 2005, 11, 440−449.
(24) Wang, T.; Yu, D.; Lamb, M. L. TRK kinase inhibitors as new
treatments for cancer and pain. Expert Opin. Ther. Patents 2009, 19,
305−319 and references therein.
(25) Bouhana, K. S.; Impastato, R.; Pheneger, J.; Jiang, Y.; Wallace, R.
D.; Do, M. G.; Zautke, N. A.; Andrews, S. W. Analgesic Effects of a
Potent and Selective Kinase Inhibitor of Neurotrophin Receptors
WO2010033941; WO2010048314; WO11006074.
the first crystal structure of TRKC with a TRKC inhibitor,
which has the potential to aid the design of other classes of
selective TRK inhibitors.
ASSOCIATED CONTENT
* Supporting Information
■
S
Experimental procedures and characterization of compounds 4,
5, 7, 16, 20, and 22; kinase selectivity and ADMET data for
compound 22; and details of in vitro and in vivo assays. This
material is available free of charge via the Internet at http://
AUTHOR INFORMATION
Corresponding Author
■
Notes
The authors declare no competing financial interest.
ACKNOWLEDGMENTS
We thank Eric Peters and Daniel Mason for HRMS data and
David Jones for NMR data.
■
REFERENCES
■
(1) Huang, E. J.; Reichardt, L. F. TRK receptors: Roles in neuronal
signal transduction. Annu. Rev. Biochem. 2003, 72, 609−642.
(2) Pierotti, M. A.; Greco, A. Oncogenic rearrangements of the
NTRK1/NGF receptor. Cancer Lett. 2006, 232, 90−98.
(3) Lei, L.; Parada, L. F. Transcriptional regulation of TRK family
neurotrophin receptors. Cell. Mol. Life Sci. 2007, 64, 522−532.
(4) Lagadec, C.; Meignan, S.; Adriaenssens, E.; Foveau, B.; Vanhecke,
E.; Romon, R.; Toillon, R. A.; Oxombre, B.; Hondermarck, H.; Le
Bourhis, X. TRKA overexpression enhances growth and metastasis of
breast cancer cells. Oncogene 2009, 28, 1960−1970.
(5) Borrello, M. G.; Bongarzone, I.; Pierotti, M. A.; Luksch, R.;
Gasparini, M.; Collini, P.; Pilotti, S.; Rizzetti, M. G.; Mondellini, P.; De
Bernardi, B.; Di Martino, D.; Garaventa, A.; Brisigotti, M.; Tonini, G.
P. TRK and ret proto-oncogene expression in human neuroblastoma
specimens: High frequency of TRK expression in non-advanced stages.
Int. J. Cancer 1993, 54, 540−545.
(6) Ma, J.; Jiang, Y.; Jiang, Y.; Sun, Y.; Zhao, X. Expression of nerve
growth factor and tyrosine kinase receptor A and correlation with
perineural invasion in pancreatic cancer. J. Gastroenterol. Hepatol. 2008,
23, 1852−1859.
(7) Zhu, Z.; Friess, H.; diMola, F. F.; Zimmermann, A.; Graber, H.
U.; Korc, M.; Buchler, M. W. Nerve growth factor expression
correlates with perineural invasion and pain in human pancreatic
cancer. J. Clin. Oncol. 1999, 17, 2419−2428.
(8) Festuccia, C.; Muzi, P.; Gravina, G. L.; Millimaggi, D.; Speca, S.;
Dolo, V.; Ricevuto, E.; Vicentini, C.; Bologna, M. Tyrosine kinase
inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the
invasive capability of prostate cancer cells in vitro. Int. J. Oncol. 2007,
30, 193−200.
(26) Okram, B; Nagle, A.; Adrian, F. J.; Lee, C.; Ren, P.; Wang, X.;
Sim, T.; Xie, Y.; Wang, X.; Xia, G.; Spraggon, G; Warmuth, M.; Liu,
Yi.; Gray, N. S. A General Strategy for Creating ‘‘Inactive-
Conformation’’ Abl Inhibitors. Chem. Biol. 2006, 13, 779−786.
(27) Melnick, J. S.; Janes, J.; Kim, S.; Chang, J. Y.; Sipes, D. G.;
Gunderson, D.; Jarnes, L.; Matzen, J. T.; Garcia, M. E.; Hood, T. L.;
Beigi, R.; Xia, G.; Harig, R. A.; Asatryan, H.; Yan, S. F.; Zhou, Y.; Gu,
X. J.; Saadat, A.; Zhou, V.; King, F. J.; Shaw, C. M.; Su, A. I.; Downs,
R.; Gray, N. S.; Schultz, P. G.; Warmuth, M.; Caldwell, J. S. An
efficient rapid system for profiling the cellular activities of molecular
libraries. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 3153−3158.
(28) Structure coordinates have been deposited with the PDB: code
3V5Q.
(9) Davidson, B.; Reich, R.; Lazarovici, P.; Nesland, J. M.; Skrede, M.;
Risberg, B.; Trope, C. G.; Florenes, V. A. Expression and activation of
the nerve growth factor receptor TRKA in serous ovarian carcinoma.
Clin. Cancer Res. 2003, 9, 2248−2259.
(10) Thiele, C. J.; Li, Z.; McKee, A. E. On TRKThe TRKB signal
transduction pathway is an increasingly important target in cancer
biology. Clin. Cancer Res. 2009, 15, 5962−5967.
(11) Martin-Zanca, D.; Hughes, S. H.; Barbacid, M. A human
oncogene formed by the fusion of truncated tropomyosin and protein
tyrosine kinase sequences. Nature 1986, 319, 743−748.
(12) Butti, M. G.; Bongarzone, I.; Ferraresi, G.; Mondellini, P.;
Borrello, M. G.; Pierotti, M. A. A sequence analysis of the genomic
regions involved in the rearrangements between TPM3 and NTRK1
144
dx.doi.org/10.1021/ml200261d | ACS Med. Chem. Lett. 2012, 3, 140−145